Diclofenac ethoxyethylamino succinyl hyaluronan - Synartro
Alternative Names: SYN 321Latest Information Update: 24 May 2023
At a glance
- Originator Synartro
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Osteoarthritis
Most Recent Events
- 27 Apr 2023 The Swedish Medical Products Agency and the Swedish Ethical Review Authority approves clinical trial application for SYN 321 in Osteoarthritis
- 24 Mar 2023 Phase-I/II clinical trials in Osteoarthritis (In adults, In the elderly) in Sweden (Intra-articular) (EudraCT2022-003633-19)
- 31 Jan 2023 Synartro submits a clinical trial application to the Swedish Medical Products Agency and the Swedish Ethical Review Authority in Sweden to conduct a phase I/IIa trial for Osteoarthritis